Compare ALPS & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALPS | SPRO |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6M | 73.4M |
| IPO Year | 2024 | 2017 |
| Metric | ALPS | SPRO |
|---|---|---|
| Price | $0.34 | $1.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 47.7K | ★ 826.9K |
| Earning Date | 07-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $0.23 | $1.08 |
| 52 Week High | $1.72 | $3.08 |
| Indicator | ALPS | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 37.08 | 45.45 |
| Support Level | $0.23 | $1.10 |
| Resistance Level | $0.44 | $1.28 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 22.10 | 16.67 |
ALPS Group Inc is an investment holding company involved in research and development, including stem cell and biotechnology-related business, and investing and managing businesses such as health and beauty centres and medical centres. The Company operates through Medical and Wellness, Life Science and Others segments. Medical and Wellness generates maximum revenue from non-surgical aesthetic services, surgical aesthetic services, medical consultation, health screenings, cellular therapy and research, and COVID-19 testing. Life Science provides whole-genome sequencing and pharmacogenomics, while Others comprises investment holding and provision of management services. The Company generates revenue in Malaysia.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.